Patient demonstrates the following clinical signs of wasting?

- a) Patient has involuntary weight loss of more than 10% of total body weight in less than four months.
  
  Weight 1: ___ Date: __________
  Weight 2: ___ Date: __________
  Weight 3: ___ Date: __________
  Weight 4: ___ Date: __________

- b) and, BMI < 18.5 (Normal BMI = 18.5 to 24.9)
  
  Patient Height = ____________
  Patient’s BMI = __________
  BMI = [wt (lbs.)/ht2 (inches)] \times 703

Clinician Certified Medical History and Current Status

1. What is the patient’s sex?  ○ Female  ○ Male
2. Is the patient a candidate for alternative treatment with testosterone or nandrolone?  ○ Yes  ○ No
   (A trial with each agent is required)

   a.) Dates of prior treatment with testosterone:
      Start date: ________  End date: ________
      Treatment (check one):  ○ Was Successful  ○ Failed
      Reason for failure: ______________________________________________________________

   b.) Dates of prior treatment with nandrolone:
      Start date: ________  End date: ________
      Treatment (check one):  ○ Was Successful  ○ Failed
      Reason for failure: ______________________________________________________________

3. Patient demonstrates the following clinical signs of wasting?

   a) Patient has involuntary weight loss of more than 10% of total body weight in less than four months;  ○ Yes  ○ No
      Weight (report at least 2 months):
      Weight 1: ___ Date: __________
      Weight 2: ___ Date: __________
      Weight 3: ___ Date: __________
      Weight 4: ___ Date: __________

   b) and, BMI < 18.5 (Normal BMI = 18.5 to 24.9)  ○ Yes  ○ No

Patient Height = ____________
Patient’s BMI = __________
BMI = [wt (lbs.)/ht2 (inches)] \times 703

Instructions

In order for a MADAP client to receive oxandrolone (Oxandrin), the client’s MADAP certification must meet the medical criteria listed on this form. The authorized prescriber must complete and submit this form for authorization. Clients must be diagnosed with HIV-related wasting syndrome as evidenced by an involuntary weight loss of more than 10% total body weight in less than four months and a BMI < 18.5 and is not a candidate for alternative treatment with testosterone or nandrolone. Male clients must have failed a clinical trial with both testosterone and nandrolone for HIV-related wasting syndrome.

FAX TO: Maryland AIDS Drug Assistance Program
Fax: (866) 440 - 9345
PA HELPDESK: (800)932-3918
Hours: Monday - Friday 8:30 am- 4:30 pm EST